NPM1-mutated AML – Medxy AI

$FDA Clears Second Menin Inhibitor — Ziftomenib (Komzifti) for Relapsed/Refractory NPM1‑Mutated AML$

FDA Clears Second Menin Inhibitor — Ziftomenib (Komzifti) for Relapsed/Refractory NPM1‑Mutated AML

By MedXY 11/13/2025

Ziftomenib is FDA-approved for adults with relapsed/refractory NPM1‑mutated AML based on single‑arm KOMET‑001 data showing a 22% remission rate and manageable toxicity including differentiation syndrome; randomized trials are planned to define clinical benefit.